ArticleFrontiers in immunology2025
Erythrocyte membrane-encapsulated SZF nanocomposites for hyperuricemia therapy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hyperuricemia is a prevalent metabolic disorder primarily induced by purine dysregulation. Current therapies face limitations due to systemic side effects and inadequate efficacy, necessitating novel treatment strategies. Methods: In this study, a biomimetic nanodrug, SZF@PDA‑RM, was synthesized by hybridizing the traditional medicine Shizhifang (SZF) with polydopamine (PDA), followed by erythrocyte membrane coating. Its physicochemical properties and reactive oxygen species (ROS)-responsive release were characterized. Results: The synthesized SZF@PDA‑RM exhibited a spherical morphology, demonstrating good stability and significant ROS-responsive drug release properties. The erythrocyte membrane coating effectively prolonged its systemic circulation. In the cellular model, SZF@PDA‑RM efficiently reduced UA-induced intracellular and mitochondrial ROS levels, restored mitochondrial membrane potential, mitigated mtDNA damage, and inhibited the activation of the NLRP3 inflammasome and the expression of downstream cytokines. Mechanistically, the nanoformulation negatively regulated mitochondrial ROS generation by promoting the interaction between SHP2 and ANT1, an effect that was reversed by SHP2 inhibitors. In the animal model, treatment with SZF@PDA‑RM significantly lowered serum uric acid, creatinine, and multiple urinary renal injury biomarkers in hyperuricemic mice. It also alleviated renal inflammatory infiltration and fibrosis, cleared renal tissue ROS, and showed no systemic toxicity. Conclusion: The erythrocyte membrane-camouflaged SZF@PDA‑RM nanocomposite achieves long circulation and targeted delivery. It exerts a multi-target synergistic therapeutic effect by directly scavenging ROS, maintaining mitochondrial homeostasis via the SHP2/ANT1 pathway, and inhibiting NLRP3-mediated inflammation, thereby effectively improving uric acid metabolism and alleviating renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.